AbCellera $ABCL builds patent-protected antibody discovery moat with microfluidics and...
Key Takeaways AbCellera leverages a proprietary platform integrating microfluidics, humanised mice, and vast datasets to accelerate antibody discovery with high specificity. The company’s competitive moat is reinforced by extensive patents,...